Kaposi sarcoma

Appraisal of therapeutic agents


  • Liron Pantanowitz MD

    Corresponding author
    1. Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts
    • Department of Pathology, Baystate Medical Center, 759 Chestnut Street, Springfield, MA 01109
    Search for more papers by this author
    • Fax: (413) 794-3195

  • See referenced original articles on pages 1083–8 and 1147–52, this issue.


Despite major advancements, the optimal treatment for Kaposi sarcoma has yet to be defined. Comparable standards employing existing therapies to satisfactorily manage all epidemiologic forms of Kaposi sarcoma, and the utilization of mechanism-based therapeutic strategies with innovative surrogate endpoints to appraise their efficacy, are required.